Newswise – SACRAMENTO – NeuroVision Imaging Inc. announced that it has received additional investment from the Alzheimer’s Drug Discovery Foundation (ADDF) – the foundation’s second round of funding for Neurovision this year – to accelerate the development of a new blood laboratory test that enables the detection and the measurement of biomarkers. for Alzheimer’s disease and other dementias before clinical onset.
The ability to measure multiple dementia-related biomarkers in the blood and correlate them with disease status and prognosis could make diagnostic testing more convenient, less invasive, and less expensive. This would not only allow researchers and clinicians to better understand the progression of the disease, but it could also improve clinical trials and the search for new treatments by providing a relatively quick and easy way to accurately monitor patient responses to treatment. .
“Our best chance to stop this disease in its tracks is to advance the most promising research around the world. The development of a blood test for the detection and monitoring of biomarkers could be a major step in this process, ”said Howard Fillit, MD, founding executive director and scientific director of ADDF. The organization is focused on rapidly accelerating the discovery of drugs to prevent, treat, and cure Alzheimer’s disease, by providing funding that allows scientists to pursue pioneering ideas that might otherwise go unexplored.
ADDF’s investment will support NeuroVision’s work to commercialize an “ultra-multiplex test” to measure several blood biomarkers associated with the development of dementia. Additionally, the project will advance Neurovision’s work on a proprietary blood test that appears to reflect beta-amyloid protein load in the brain. Amyloid begins to accumulate in the brain about 20 years before symptoms of Alzheimer’s disease appear.
“There are a few ultra-sensitive technologies capable of detecting exceptionally low concentrations of the major biomarkers of Alzheimer’s disease in the blood, but the platforms are not easily scalable to meet commercial demands and they are difficult to customize for testing. multiplex, ”said Steven R. Verdooner, CEO and co-founder of NeuroVision. “Neurovision holds the exclusive rights to a technology combining ultra-sensitivity, multiplexing capability and ease of use. The result is an exceptionally robust tool.
Leyla Anderson, MD, Ph.D., D (ABMLI), vice president of biomarker development at NeuroVision, leads the company’s biomarker studies with Hugo Vanderstichele, Ph.D., global head of biomarker development.
Anderson, board-certified in Medical Laboratory Immunology, said the type of technology used by NeuroVision – bringing together traditional immunoassay principles with integrated circuit design and nanofabrication – transfers level lab studies research in clinical settings. Thanks to the system’s highly reactive nanosensor, once labeled with magnetic nanoparticles, disease biomarkers can be immediately detected in real time.
“These studies are designed to optimize and then validate each of our prototype tests – individually and in combination – to predict cerebral amyloid in subjects ranging from those cognitively normal to those with mild cognitive impairment to those with Alzheimer’s disease.” , Anderson said. “We hope the results will provide powerful, easy-to-access tools that will stimulate research in Alzheimer’s disease and improve the way clinicians and patients manage the disease. We expect these tests to be commercially available in 2022. ”
By the time the symptoms of Alzheimer’s disease appear, serious brain changes have already taken place. NeuroVision is focused on providing diagnostic tests and biomarkers for early detection and monitoring.
The ADDF Diagnostic Accelerator (DxA), created in July 2018, is a donor partnership with commitments totaling nearly $ 50 million over three years. Partners include ADDF co-founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation and the Association for Frontotemporal Degeneration, among others. The objective of DxA is to develop new biomarkers for the early detection of Alzheimer’s disease and related dementias.
This initiative aims to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and associated dementias and to advance the clinical development of more targeted treatments. Through translational research awards and access to expert advice from industry, this initiative will challenge, assist and fund the research community, both in academia and industry, to develop new peripheral and digital biomarkers.
# # #
About NeuroVision Imaging Inc.
NeuroVision (neurovision.com) was established in 2010 and is headquartered in Sacramento, California. The company is dedicated to the development and supply of diagnostic solutions for neurodegenerative and ophthalmic diseases. The company team has extensive experience in fluid biomarkers, imaging and data science.
About the Alzheimer’s Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. ADDF is the only public charity focused solely on funding drug development for Alzheimer’s disease, using a risk-taking model of philanthropy to support research in universities and the biotech industry. Thanks to the generosity of its donors, ADDF has provided more than $ 168 million to fund more than 650 Alzheimer’s disease drug and biomarker discovery programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/.